ArticleGut pathogens2018
Proliferation of enterotoxigenic
Article in Gut pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Kinetics of Enteric Pathogen Quantity During Acute Diarrhea in Children in Resource-Limited Settings.Open forum infectious diseases · 2026Article
- Inflammation, the kynurenines, and mucosal injury during human experimental enterotoxigenic Escherichia coli infection.Medical microbiology and immunology · 2024Article
- Reduced Plasma Guanylin Levels Following EnterotoxigenicMicroorganisms · 2023Article
- Strong Association between Diarrhea and Concentration of EnterotoxigenicPathogens (Basel, Switzerland) · 2023Article
- Linking inherent O-Linked Protein Glycosylation of YghJ to Increased Antigen Potential.Frontiers in cellular and infection microbiology · 2021Article
- Human Mucosal IgA Immune Responses against EnterotoxigenicPathogens (Basel, Switzerland) · 2020Review
- Experimental Infection of Human Volunteers with the Heat-Stable Enterotoxin-Producing EnterotoxigenicPathogens (Basel, Switzerland) · 2019Article
- Characterizing the Personalized Microbiota Dynamics for Disease Classification by Individual-Specific Edge-Network Analysis.Frontiers in genetics · 2019Article
- Antioxidant Properties, Phytoactive Compounds and Potential Protective Action ofDose-response : a publication of International Hormesis SocietyArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs part of the effort to develop an enterotoxigenic
resultsFor 6 of the 9 volunteers, the stool TW11681 DNA concentration increased sharply a median 3.5 (range 2-5) days after dose ingestion, peaking at a median of 5.4% (range 3.3-8.2%) of the total DNA in the specimen. The concentration then fell sharply during the subsequent days, sometimes even before the onset of antibiotic treatment. The size or timing of these proliferation peaks did not seem to be associated with the number of TW11681 bacteria ingested, but the 2 volunteers who developed diarrhea and all five who experienced abdominal pains or cramps had these peaks. The 3 volunteers who did not have the proliferation peaks experienced fewer symptoms and they generally had relatively low CfaB- and YghJ-specific antibody levels before ingesting the strain and subsequently weaker responses than the other volunteers afterwards.
conclusionsSince the lack of proliferation peaks appears to be associated with fewer clinical symptoms and lower serum antibody responses to virulence factors of the infecting strain, it may be important to account for proliferation peaks when explaining results from controlled human infection model studies and for improving the accuracy of protective efficacy estimates when testing new ETEC diarrhea vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.